Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma
Stopped: Lack of funding
United States4 participantsStarted 2006-11
Plain-language summary
The purpose of this study is to test if secretin-enhanced CT is a useful noninvasive screening tool for pancreatic cancer in a high-risk population.
Who can participate
Age range35 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Persons 50 years or older with recently diagnosed diabetes (within 2 years), with at least one of the following: no family history of diabetes, abdominal discomfort, anorexia, weight loss, elevated serum CA 19-9, or those undergoing EUS with or without Fine Needle Aspiration (FNA) for pancreatic cancer screening ; OR
* Persons 35 years old or older with familial pancreatic cancer with 2 or more first degree relatives with pancreatic cancer; OR
* Persons 35 years old or older with Peutz-Jeghers syndrome; OR
* Persons 35 years old or older with suspicious clinical symptoms of pancreatic cancer, but had normal CT of the abdomen with iodinated contrast within 2 weeks.
Exclusion Criteria:
* Persons with contraindication to iodinated contrast
* Allergy to iodinated contrast
* Renal insufficiency (serum creatinine \> 1.5 mg/dl)
* Patients with contraindication to ionizing radiation
* Pregnancy
* Patients with previous pancreatic surgery
* Contraindication to secretin
* Allergy to secretin
* Acute pancreatitis
What they're measuring
1
Number of Subjects With Evidence of Pancreatic Tumor or Any Secondary Findings of Pancreatic Tumor as Shown by CT.